Latest Breaking News On - ஷெபா நிதி - Page 1 : comparemela.com

Share this article Share this article TEL AVIV, Israel, March 9, 2021 /PRNewswire/ SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered an agreement with The Sheba Fund for Health Services and Research, to perform a pre-clinical study for the evaluation of the Company s SCI-210 drug development program, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol  (CBD)and palmitoylethanolamide (PEA) for the treatment of Status Epilepticus (SE). The pre-clinical study that the Company expects to conduct is expected to investigate the potential advantage of its proprietary combination of SCI-210 by harnessing the entourage effect phenomenon, originally coined by Prof. Mechoulam. The effect of SCI-210 will be compared to CBD single treatment in animal model (mice) of SE.

Adi zuloff shaniExchange commissionScisparc ltdSheba fund for health servicesTherapix biosciences ltdDrug administrationPrnewswire scisparc ltdSheba fundHealth servicesStatus epilepticusChief technologiesLooking statementsPrivate securities litigation reform actAnnual reportபரிமாற்றம் தரகுஷெபா நிதி க்கு ஆரோக்கியம் சேவைகள்